Publications by authors named "Daniel Heintel"

Claim this Profile
E
Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis.
Dora Niedersuess-Beke, Karl Mayrhofer, Johanna Krauter, Johannes Franke, Dominic Vais, Daniel Heintel

Int J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study.
Dora Niedersuess-Beke, Karl Mayrhofer, Johanna Krauter, Susanne Schnabel, Simon Peter Gampenrieder, Daniel Heintel

Clin Genitourin Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Moritz Fürstenau, Arnon P Kater, Sandra Robrecht, Julia von Tresckow, Can Zhang, Daniel Heintel

Lancet Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders.
Christoph Kornauth, Tea Pemovska, Gregory I Vladimer, Günther Bayer, Michael Bergmann, Daniel Heintel

Cancer Discov· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.
Christoph Kornauth, Charles Herbaux, Bernd Boidol, Chantal Guillemette, Patrick Caron, Daniel Heintel

Haematologica· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.
Markus C Stühlinger, Ansgar Weltermann, Philipp Staber, Daniel Heintel, Thomas Nösslinger

Wien Klin Wochenschr· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Arnold Bolomsky, Wolfgang Hübl, Stefano Spada, Ercan Müldür, Karin Schlangen, Daniel Heintel

Am J Hematol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.
Heinz Ludwig, Elisabeth Rauch, Thomas Kuehr, Zdeněk Adam, Adalbert Weißmann, Daniel Heintel

Haematologica· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.
Arnold Bolomsky, Dirk Hose, Martin Schreder, Anja Seckinger, Susanne Lipp, Daniel Heintel

J Hematol Oncol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cereblon expression in multiple myeloma: not ready for prime time - response to Lodé et al.
Niklas Zojer, Daniel Heintel, Antonio Palumbo, Heinz Ludwig

Br J Haematol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein lipase in chronic lymphocytic leukaemia - strong biomarker with lack of functional significance.
Edit Porpaczy, Stefanie Tauber, Martin Bilban, Gerhard Kostner, Michaela Gruber, Daniel Heintel

Leuk Res· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
Daniel Heintel, Alberto Rocci, Heinz Ludwig, Arnold Bolomsky, Simona Caltagirone

Br J Haematol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
Ulrich Jäger, Michael Fridrik, Markus Zeitlinger, Daniel Heintel, Georg Hopfinger

Haematologica· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.
Michaela Gruber, Karin Fleiss, Edit Porpaczy, Cathrin Skrabs, Alexander W Hauswirth, Daniel Heintel

Ann Hematol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
Antonia Lopez-Girona, Daniel Heintel, Ling-Hua Zhang, Derek Mendy, Svetlana Gaidarova

Br J Haematol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age.
Daniel Heintel, Cathrin Skrabs, Alexander Hauswirth, Karin Eigenberger, Christine Einberger

Ann Hematol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia.
Birgit Kainz, Medhat Shehata, Martin Bilban, Dirk Kienle, Daniel Heintel

Int J Cancer· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16).
Birgit Kainz, Daniel Heintel, Rodrig Marculescu, Ilse Schwarzinger, Wolfgang Sperr

Hematol J· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B-cell lymphoma and arterial esophageal bleeding.
Eva Feierl, Clemens Dejaco, Daniel Heintel, Andreas Wagner, Sheila Chatwani

Gastrointest Endosc· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burkitt lymphoma following splenic marginal zone lymphoma. evidence for two independent B-cell clones.
Daniel Heintel, Berthold Streubel, Natascha Welzel, Trang Le, Ilse Schwarzinger

Cancer Genet Cytogenet· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis